Abstract
Non-melanoma skin cancer (NMSC) is the most common cancer among Caucasian populations worldwide. More than 1 million new NMSCs are diagnosed each year, making it the most common cancer in the United States. Basal cell carcinomas (BCCs) account for about 80% of NMSCs, and most of the remainder are squamous cell carcinomas (SCCs) [1]. The treatment of advanced-stage NMSCs is challenging as surgical excision becomes impossible. Recent advances in the treatment of these tumors include targeted molecular therapies against epidermal growth factor receptor (EGFR) and hedgehog signaling pathway.
Citation
Lutay N. Targeted Molecular Therapies for Non-Melanoma Skin Cancer. SM Dermatolog J. 2015; 1(1): 1002.